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Objectives: The aim of this systematic literature review was to summarize the current knowledge
regarding the prevalence of, time to recovery from, and inﬂuence of glucocorticoid dose and duration on
glucocorticoid-induced adrenal insufﬁciency (AI).
Methods: Eligible studies were original research articles, which included adult patients with an
indication for glucocorticoids and measured adrenal function following exposure to systemic glucocorti-
coids. Searches were performed in Web of Science and MEDLINE, with further articles identiﬁed from
reference lists. Screening was performed in duplicate. Data were extracted for each group of
glucocorticoid-exposed patients within eligible studies. The reported proportion of patients with AI
was summarized as median and inter-quartile range. Results were then stratiﬁed by daily dose,
cumulative dose, duration of exposure and time since last glucocorticoid use. The risk of bias within
and across studies was considered: for randomised controlled trials risk of bias was assessed using the
tool developed by the Cochrane Collaboration.
Results: Overall, 73 eligible studies were identiﬁed out of 673 screened. The percentage of patients with
AI ranged from 0% to 100% with a median (IQR) ¼ 37.4% (13–63%). Studies were small—median (IQR)
group size 16 (9–38)—and heterogeneous in methodology. AI persisted in 15% of patients retested 3 years
after glucocorticoid withdrawal. Results remained widely distributed following stratiﬁcation. AI was
demonstrated at o5 mg prednisolone equivalent dose/day, o4 weeks of exposure, cumulative dose
o0.5 g, and following tapered withdrawal.
Conclusions: The heterogeneity of studies and variability in results make it difﬁcult to answer the
research questions with conﬁdence based on the current literature. There is evidence of AI following low
doses and short durations of glucocorticoids. Hence, clinicians should be vigilant for adrenal insufﬁciency
at all degrees of glucocorticoid exposure.
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Introduction
Adrenal insufﬁciency (AI) is failure of the adrenal cortex to
produce sufﬁcient levels of cortisol. Chronically low cortisol levelsHS Journals, Inc. This is an open a
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. Dixon).can cause non-speciﬁc symptoms such as fatigue and nausea
whilst lack of the usual cortisol response to stress can lead to a
potentially fatal adrenal crisis [1]. Taking glucocorticoids (GCs) can
lead to suppression of the hypothalamic–pituitary–adrenal (HPA)
axis. The HPA-axis may remain suppressed following cessation of
GC therapy, leaving the patient with adrenal insufﬁciency [2].
GCs are widely used therefore many patients could potentially
be at risk of AI. In 2008, almost 1% of the UK adult population were
exposed to oral GCs [3], including 0.79% on long-term courses
(longer than 3 months) [4], and over 8 million prescriptions for
oral GCs were issued in England during April 2014–March 2015 [5].
While there is limited published data around the clinical impact,
one recent study suggests 6% of patients presenting at hospitalccess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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novel treatments aimed at improving the beneﬁt:risk ratio of
glucocorticoids (selective glucocorticoid receptor agonists, SEG-
RAs), which are currently being trialed, are unlikely to alter the
risk of adrenal insufﬁciency. This is because AI is believed to result
from the same mechanism that mediates the beneﬁcial anti-
inﬂammatory effects of glucocorticoids [7,8].
AI has been a recognized side-effect of GC therapy since the
early 1950s [9–11]; despite this, the risk of developing
GC-induced AI remains unclear. Prevalence estimates from some
of the larger observational studies range from 14% to 63%
[12–15]. It is also unclear whether or not the dose and duration
of GC use affects the risk of developing AI: Schlaghecke et al. [12]
found no relationship between either the dose or duration of
therapy and AI, while Jamilloux et al. [13] found both cumulative
dose and treatment duration to be associated with an increased
risk of AI.
The aim of this systematic review was to summarize the
published literature investigating GC-induced AI in adults. Spe-
ciﬁc objectives were to investigate (1) the prevalence of GC-
induced adrenal insufﬁciency, (2) the time course of adrenal
recovery following cessation of GC therapy and (3) the associa-
tion between the dose and duration of GC therapy and the
prevalence of adrenal insufﬁciency.Methods
Eligibility criteria
Original research articles that tested adrenal function following
exposure to glucocorticoids were identiﬁed. The population of
interest were adult patients treated for the most common gluco-
corticoid indications as reported by van Staa et al. [16] for UK
primary care data. These indications were disorders of the respi-
ratory system; skin or subcutaneous tissue; musculoskeletal sys-
tem or connective tissue; nervous system; digestive system;
circulatory system; or neoplasms. Glucocorticoid use was limited
to systemic routes including oral, intravenous, intramuscular, and
subcutaneous. Finally, eligible papers were required to report the
numbers of patients with normal/sub-normal HPA-axis function
test results rather than presenting the average cortisol levels for
study groups.
During data extraction, the following additional eligibility
criteria were applied: papers were excluded if (1) participants
aged under 16 were included; (2) glucocorticoids were taken less
than 12 h before the HPA-axis function test; (3) glucocorticoid
indications were unspeciﬁed; (4) the daily dose, duration and
cumulative dose of GCs were all unreported; (5) it was clear that
patients were using local GCs (topical, inhaled or intra-articular)
during the study window; and (6) patients were pregnant or
critically ill, were being treated with megestrol acetate, had
metastatic cancer or were being treated peri-operatively (all
potential confounders). Where it was possible to remove individ-
ual patients who met these exclusion criteria from the results, the
paper was retained.
Published or in-press articles were included. There was no time
restriction and non-English language articles were translated using
Google Translate [17].
Information sources
The search was performed in MEDLINE (1946-present) and
Web of Science (1900-present). In addition, the reference lists of
eligible papers were screened to identify further papers missed in
the database search.Search strategy
The search included terms for adult humans, the indications
described in Section Information sources, systemic glucocorti-
coids/named drug substances, and adrenal insufﬁciency/HPA-axis
tests. The full search strategy is available in Supplementary File 1.
Papers with only local glucocorticoids, in children or adolescents,
or where the glucocorticoid was used as steroid cover/replacement
therapy (e.g., in patients with Addison0s disease) were excluded. In
the Web of Science search, the explicit mention of the HPA-axis,
adrenal gland, or cortisol in the title of the article was required due
to a large number of results in initial searches. The SIGN strategy
search ﬁlters [18] were used to limit the MEDLINE results to
clinical trials or observational studies. The Web of Science search
was limited to journal articles, abstracts and proceedings. The
latest search was performed on November 25, 2014.
Study selection
The initial screening of search results by title and abstract was
carried out in duplicate (R.J. and A.L.H.). Where there was dis-
agreement, the article was discussed between the two reviewers
and if there was still uncertainty the article was retained. Full texts
were then assessed, in duplicate, for eligibility. Disagreements
were resolved by discussion. The reference lists of eligible articles
were then screened, and the eligibility of any articles identiﬁed
was then checked in duplicate as before.
Data extraction
Data were extracted using pre-designed forms. If a paper
included multiple groups of GC-exposed patients, data were
extracted for each group rather than pooling the data. For example,
Suzuki et al. [19] compared patients exposed to 9 mg budesonide to
patients exposed to 15 mg budesonide: data were extracted for each
of these groups separately. Information extracted included the study
design, number of participants, the age/gender distributions and
indication, about comorbidities or other medications used; the GC
indication; drug substance, route, dose, and duration; the type of
HPA-axis test performed, and the criteria used to deﬁne AI, and the
numbers of patients tested and the number of patients with AI.
Summary measures
The data extracted are summarized in Table 1. The proportion of
patients with AI in each group was extracted, and the data
summarized using the median, inter-quartile range (IQR), and range.
Summaries are presented for all groups and then stratiﬁed according
to GC exposure, with dose converted to the prednisolone equivalent
dose (Supplementary File 2). Groups were stratiﬁed by daily dose
(o5 mg/day; 5–10 mg/day, 10–20 mg/day; 20þ mg/day), duration
(o4weeks, 4–52weeks, 52þweeks) and cumulative dose (o0.5 g,
0.5–5 g, 5þ g). To investigate the time to adrenal recovery, groups
were further stratiﬁed according to the timing of the test with
respect to the last dose of GCs, limited to groups exposed to oral GCs
only. These results were summarized as for the dose/duration; in
addition, summaries of individual studies that tested patients multi-
ple times after cessation of GCs are presented. Studies that used a
tapered dose of GCs are also summarized individually.
Risk of bias/study quality
The Cochrane Collaboration0s tool for assessing the risk of bias
[20] was applied to the randomised controlled trials (RCTs) included
in the review, including an additional section to assess the risk of
confounding in these studies. The quality of reporting and
Table 1
Summary characteristics of the groups included in the review.
Characteristics by group Overall (n ¼ 100) Study design Observational (n ¼ 76)
RCT (n ¼ 24)
Total number of patients tested 3166 795 2371
Median (IQR) number of patients tested 16 (9–38) 25 (17–48) 14.5 (8–36)
Range number of patients tested 2–399 7–86 2–399
Median (IQR) average age* 45 (36–53) 35.5 (33–37) 48 (41–54)
Median (IQR) % female* 51 (40–67) 58.5 (32–67) 50 (40–67)
Glucocorticoid indication
Musculoskeletal 25 3 22
Respiratory 24 7 17
Neoplasms 4 0 4
Digestive system 19 14 5
Nervous system 3 0 3
Transplant 7 0 7
Multiple 18 0 18
Drug substances
Prednisone 17 4 13
Prednisolone 24 6 18
Budesonide 16 14 2
Methylprednisolone 8 0 8
Triamcinolone 5 0 5
Dexamethasone 4 0 4
Other (hydrocortisone, paramethasone, ﬂuocortolone) 4 0 4
Unclear 5 0 5
Multiple 17 0 17
Glucocorticoid Route
Oral 87 24 63
IM 5 0 5
IV 3 0 3
Multiple 5 0 5
Dose category**
o5 mg/day 15 8 7
5–20 mg/day 42 13 29
20þ mg/day 23 3 20
Unknown 20 0 20
Duration category
o4 weeks 15 4 11
4–52 weeks 36 20 16
52þ weeks 37 0 37
Unknown 12 0 12
Cumulative dose category**
o0.5 g 27 19 8
0.5–5 g 24 5 19
5þ g 13 0 13
Unknown 36 0 36
Adrenal function test
Short ACTH test 57 17 40
Insulin tolerance test 14 0 14
ACTH infusion 8 5 3
CRH test 6 0 6
Metyrapone test 4 0 4
Plasma cortisol 8 2 6
Urinary cortisol 2 0 2
Multiple 1 0 1
RCT, randomised controlled trial; IQR, inter-quartile range; IM, intra-muscular; IV, intravenous; ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone.
Unless otherwise indicated, ﬁgures represent the number of studies with that characteristic.
n Results may be for whole group not necessarily those tested. May be pooled for the whole study. 17/100 groups missing age; 15/100 groups missing gender.
nn Prednisolone equivalent dose.
R.M. Joseph et al. / Seminars in Arthritis and Rheumatism 46 (2016) 133–141 135heterogeneity of the other included studies, and the potential for
bias across studies, are commented on in the results and discussion.
Results
In total, 673 articles were screened and 73 studies were
included in the ﬁnal review (Fig. 1). Within the 73 studies there
were 100 groups of GC-exposed patients and a total of 3166patients. A summary of these groups is presented in Table 1, while
a condensed version of the data extraction table can be seen in
Supplementary File 3. There were thirteen RCTs [19,22–33] with
random allocation and blinding maintained throughout; the
remaining 60 studies were classiﬁed as observational studies
[12–15,34–84] with some open trials [85–88] and pilot studies
[89]. The majority of groups were small (median ¼ 16 patients).
The most frequent GC indications were musculoskeletal,
Fig. 1. Flow diagram showing the study selection process. Based on the PRISMA 2009 ﬂow diagram [21]. Abbreviations: AI, adrenal insufﬁciency; GC, glucocorticoid.
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GCs investigated were prednisolone, prednisone, and budesonide.
The majority of studies investigated oral GCs.
Across all of the groups the median percentage of patients
found to have adrenal insufﬁciency was 37.4% (IQR: 13–63%), and
this was similar for RCTs (median ¼ 37.4%, IQR: 11–60%) and
observational studies (median ¼ 37.2%, IQR: 13–63%). Results were
widely distributed in each category, with a range of 0–92% for RCTs
and 0–100% for observational studies.
Table 2 shows the proportion of patients with AI for those taking
oral GCs stratiﬁed by the timing of the test with respect to their most
recent dose. Some patients were found to have adrenal insufﬁciency
when tested more than 30 days after their last oral GC dose. In nine
studies, patients were retested several times after GC withdrawal
(Fig. 2). The number of patients retested ranged from 1 [61,89] to 48
[13]. Excluding the studies retesting a single patient, the percentage
of patients with AI persisting at the end of follow-up ranged fromTable 2
Percentage of patients per group with AI by time since last dose (oral
glucocorticoids only).
Time since
last dose
Total number
of patients
Number of
groups
Median
(range)
group size
Median
(IQR), % AI
Range,
% AI
Up to
1 day
2542 63 21 (3–399) 40.9 (20–63) 0–100
2–6 days 323 20 10 (2–75) 35.9 (0–71) 0–90
7–29 days 49 2 24.5 (4–45) 16.7 (0–33) 0–33
30þ days 31 2 15.5 (15–16) 47.9 (27–69) 27–69
IQR, inter-quartile range; AI adrenal insufﬁciency.75% (after 10 weeks of cessation) [48] to 15% (after 3 years of
cessation) [13,73]. Four studies followed patients for at least 1 year
and in these studies the percentage of patients with persisting AI
ranged from 15% to 67% [13,14,73,75]. It was not always clear which
patients had been selected for follow-up and two studies lost a large
proportion of patients to follow-up (35–40%) [13,73].
There was no obvious pattern when stratifying by the dose,
duration or cumulative dose (Table 3). Across all strata, the median
percentage of patients with adrenal insufﬁciency ranged from 14%
(IQR: 0–40%) for a medium cumulative dose (0.5–5 g) to 50% (IQR:
35–66%) for a high cumulative dose (greater than 5 g).
A total of 13 studies tested adrenal function after a GC taper and
these are summarized in Table 4. The median percentage of
patients with AI after a GC taper was 38% and ranged from 0% to
84%. The studies varied in the initial GC doses, duration of tapering
and prior exposure pattern.
The risk of bias assessment for RCTs is presented in
Supplementary File 4. Where reported, studies scored a low risk in
most domains. In many cases, however, insufﬁcient information was
provided on which to base a judgement. The risk of attrition bias
scored poorly: three out of the 13 RCTs reported outcomes for all
tested patients; in the remaining papers it was either impossible to
calculate the number of patients tested or the outcome was missing
for some patients with no explanations. The risk of confounding was
high for many of the studies: in seven of the studies, some patients
demonstrated abnormal HPA-axis function at baseline.
The risk of confounding is likely to be high in the observational
studies: there was no information at all about concurrent medical
conditions for 56 of the 76 groups, and no information about
concurrent treatments in 46 groups. The exclusion of any local GC
use was explicitly mentioned for 17 of the groups and therefore
Fig. 2. Adrenal recovery over time. Abbreviations: AI adrenal insufﬁciency; GC,
glucocorticoid; d, day; w, week; y, year. Each point represents a study in which
HPA-axis tests were repeated at least once following withdrawal of GC therapy (in
all patients, in patients with AI at the initial test, or in a subset of the latter).
Horizontal axis: time between the ﬁnal GC dose and the ﬁnal test performed during
the study. Vertical axis: percentage of patients found to have AI at the ﬁnal test.
Points are labeled with the total number of patients retested during the studies,
including those who did and did not recover by the end of follow-up. The size of
the point reﬂects the number of patients retested.
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be seen in Table 1, which shows the range of indications, drug
substances, routes and adrenal function tests used. In general very
few details were provided regarding patient selection, and loss to
follow-up was difﬁcult to ascertain.Discussion
Across the 100 GC-exposed participant groups included in this
review, the median prevalence of AI was 37%. Whilst this ﬁgure is
in line with the estimates of the larger observational studies
(14–63% [12–15]), it is unlikely to be a meaningful prevalence
estimate given the wide distribution of our results and resultant
imprecision. Most studies retesting patients after GC withdrawal
found evidence of persisting AI, including 15% of patients retested
after 3 years of cessation (Fig. 2), yet from the current literature it
is not possible to describe a time course for adrenal recovery.
There is also evidence that AI may persist for more than 3 yearsTable 3
Percentage of patients per group with AI by glucocorticoid dose, duration or cumulativ
Total number of patients Number of groups
Average daily dose*
o5 mg/day 371 15
5–10 mg/day 703 22
10–20 mg/day 623 16
20þ mg/day 527 26
Duration
o4weeks 378 15
4–52 weeks 1533 36
52þ weeks 1093 37
Cumulative dose*
o0.5g 702 28
0.5–5g 804 23
5þ g 491 13
IQR inter-quartile range; AI adrenal insufﬁciency
n Prednisolone equivalent dose.after GC withdrawal. When results were stratiﬁed according to the
average dose, duration and cumulative dose of GCs used within
groups, no clear trends were revealed. Within the stratiﬁcations,
results were still widely distributed and AI was demonstrated even
in the lowest exposure categories. AI was also found in studies
which included a tapered reduction in dose.
It has not been possible to address any of our research
questions adequately, based on over sixty years of published
literature. There are several factors that would contribute to the
wide distribution of the results. Firstly, the studies found were
heterogeneous, including variation in indications and GC type,
dose, and duration. There was also variability in methods of
outcome assessment: while the short ACTH test (standard or low
dose) was the most frequently used, a range of other tests
including the insulin tolerance test (the gold-standard), ACTH
infusion and CRH test were also used. Even within the same test,
the cutoff values used to deﬁne AI varied from study to study. This
heterogeneity in study methods is likely to increase the variability
in the results and make it difﬁcult to appropriately summarize the
ﬁndings. Nonetheless, stratiﬁcation led to no greater clarity in the
results. Secondly, the group sizes included were small—50% had
fewer than 16 patients—and so the individual prevalence estimates
for each group are less precise. Another factor is having only
group-level exposure data; for the majority of studies the dose and
duration of GC use within the groups were variable and basing the
stratiﬁcation on average values may be one reason no obvious
trends were apparent.
In addition to these, it is possible that bias was present within
and across studies, although in most cases there was not enough
evidence to be able to comment on the risk of bias. Only 6 of the
62 observational studies were published after the publication of
the STROBE statement [90] in 2007 and few details were provided
in any of the observational studies regarding the selection and
recruitment of patients, how GC exposure was assessed, any loss to
follow-up, or any comorbidities or therapies that may have
confounded the results. While the majority of the RCTs were
published after the publication of the CONSORT statement [91],
many still lacked sufﬁcient detail in some of the domains. This
included incomplete outcome reporting making it difﬁcult again to
judge the risk of attrition bias for most studies. Importantly, many
of the RCTs reported evidence of adrenal insufﬁciency prior to
exposure to the study drug making it difﬁcult to attribute AI to the
effects of the study drug. There is also potential for bias across
studies, although plotting the % AI against the group size did not
reveal any obvious gaps (Supplementary File 5). It is possible that
some patient groups are underrepresented in the literature: vane dose.
Median (range) group size Median (IQR), % AI Range, % AI
21 (6–63) 22.7 (11–36) 0–62
22 (7–86) 43.7 (38–58) 14–80
19 (3–279) 33.3 (22–80) 0–100
8 (2–100) 16.3 (0–71) 0–100
9 (4–86) 36.4% (0–89%) 0–100%
20 (5–399) 33.9% (12–55%) 0–92%
19 (3–150) 42% (26–65%) 0–100%
19 (2–86) 35.4% (11–54%) 0–100%
10 (4–279) 14% (0–40%) 0–89%
23 (3–150) 50% (35–66%) 0–100%
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R.M. Joseph et al. / Seminars in Arthritis and Rheumatism 46 (2016) 133–141138Staa et al. [16] demonstrated that the most frequently recorded
indication for oral GCs was respiratory disease (40% of GC users),
yet 24% of the papers focused on respiratory disease, compared to
25% for musculoskeletal and 19% for gastro-intestinal conditions
(Table 1).
While this manuscript was in preparation, Broersen et al. [92]
published a systematic review on the same subject, with similar
research questions and methods. The authors used a logistic
regression model to generate pooled estimates of the percentage
of patients with adrenal insufﬁciency; their overall result for
patients using oral GCs was 48.7% (95% CI: 36.9–60.6). We decided
at study inception, before our ﬁnal search and data extraction, not
to perform a meta-analysis, based on the heterogeneity shown in
a few key references. Broersen et al. examined the association
with GC dose and duration in asthma patients only, to create a
more homogeneous population. Their results suggest an
increased risk of AI associated with increased dose and duration
of GCs, although conﬁdence intervals overlapped. No such pattern
was seen within our whole study population.
A strength of our study is the rigorous methodology followed,
in duplicate, to identify suitable studies and extract data. It is
reassuring that, despite slight differences in search strategy,
including restricting our database searches to certain GC indica-
tions, the included studies overlap almost completely with those
of another, independent, group [92]. This suggests that our search
strategy was effective. We did not restrict results to English-
language papers or a minimum study size, therefore we have
included some additional papers compared to the study of
Broersen et al. A possible weakness is the fact we tightened the
eligibility criteria during data extraction, as described in the
methods. The reason for this was the lack of detail and ambiguity
in many of the articles, which became increasingly apparent
when looking at papers in increasing detail and led us to write
out a strict list of inclusion/exclusion criteria for this stage. We did
not perform a risk of bias assessment for the observational studies
because the quality of reporting was poor in the majority of
studies, therefore, it would not have been possible to give a
judgement of high/low risk in many cases.
From our results, it is clear that research is still needed into the
risk of AI following GC exposure. Future studies should aim to
have a sufﬁcient sample size to estimate the prevalence of adrenal
insufﬁciency with conﬁdence. Studies could include patients who
have been withdrawn from GCs as there remains a lack of
published data regarding how long adrenal insufﬁciency persists.
There is also a lack of published research regarding differing
tapering schedules, a question potentially suited to a randomised
controlled trial design. Finally, accurate patient-level data regard-
ing GC exposure is important if the dose and duration is to be
studied: ideally studies should include long-term prospectively
collected data. Alongside these considerations, it is vital that
quality of reporting is increased so that the generalizability, risk of
bias and potential confounding can be assessed. Use of available
guidelines, such as the STROBE [90] or CONSORT [91] statements,
should ensure all important items are reported in future articles.
Our study raises questions for clinicians prescribing GC ther-
apy. The major endocrinology societies (Endocrine Society [United
States], Society for Endocrinology [United Kingdom], European
Society of Endocrinology) do not currently issue clinical guidance
on reducing GC-induced AI. UK clinicians can turn to the British
National Formulary [93] and the National Institute for Health and
Care Excellence Clinical Knowledge Summary [94], which both
advise gradual GC withdrawal if patients have taken: more than
40 mg prednisolone (or equivalent) daily for more than one week;
repeated GC doses in the evening; GCs for more than three
weeks; a short course of GCs within one year of stopping long-
term GC therapy; or have other risk factors for adrenal
R.M. Joseph et al. / Seminars in Arthritis and Rheumatism 46 (2016) 133–141 139suppression. With regards to tapering, they advise rapid reduction
to a physiological GC dose (7.5 mg prednisolone daily or equiv-
alent), and slow reduction thereafter. However, our study suggests
that the evidence base supporting these recommendations is not
robust. Furthermore, we highlight that studies demonstrate AI at
all levels of GC exposure, even low dose and after tapering. We
therefore suggest that clinicians be vigilant for GC-induced AI with
all degrees of GC exposure, and counsel patients accordingly.
Anecdotally, testing for adrenal insufﬁciency in patients with
chronic GC exposure is infrequent. Adrenal function can be tested
using the short ACTH stimulation test (250 mg), as performed in
57% groups in this study; this produces equivalent results to the
gold-standard insulin tolerance test (used in 14%), but is safer, and
carries good long-term predictive value [95,96]. Regarding who
should be tested, and when, there is an imperative need for high
quality, prospective studies to better guide clinicians, and reduce
patient morbidity.Contributorship statement
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